IceCure Medical (ICCM) Projected to Post Earnings on Tuesday

IceCure Medical (NASDAQ:ICCM) is expected to be posting its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect IceCure Medical to post earnings of ($0.03) per share and revenue of $1.3440 million for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 11:00 AM ET.

IceCure Medical (NASDAQ:ICCM) last released its earnings results on Sunday, February 15th. The company reported $0.06 earnings per share for the quarter. IceCure Medical had a negative return on equity of 221.04% and a negative net margin of 445.61%.The company had revenue of $1.28 million during the quarter. On average, analysts expect IceCure Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

IceCure Medical Trading Down 4.0%

NASDAQ ICCM opened at $0.24 on Friday. IceCure Medical has a 1-year low of $0.24 and a 1-year high of $1.40. The stock has a 50-day moving average of $0.45 and a 200-day moving average of $0.59. The firm has a market cap of $19.48 million, a PE ratio of -1.00 and a beta of 0.47.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in IceCure Medical stock. Virtu Financial LLC purchased a new stake in shares of IceCure Medical Ltd. (NASDAQ:ICCM) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 64,524 shares of the company’s stock, valued at approximately $39,000. Virtu Financial LLC owned 0.09% of IceCure Medical at the end of the most recent reporting period. 0.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ICCM shares. Weiss Ratings reissued a “sell (e+)” rating on shares of IceCure Medical in a research note on Tuesday, April 21st. Alliance Global Partners began coverage on IceCure Medical in a research note on Monday, May 4th. They issued a “buy” rating for the company. Finally, Wall Street Zen raised shares of IceCure Medical from a “sell” rating to a “hold” rating in a research report on Saturday, February 7th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $2.64.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.